HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma. Under the terms of this agreement Scil Proteins will license the microbial based manufacturing process for recombinant human Nerve Growth Factor (rhNGF) to Anabasis.
